ArticleMolecules (Basel, Switzerland)2021
Longitudinal Bottom-Up Proteomics of Serum, Serum Extracellular Vesicles, and Cerebrospinal Fluid Reveals Candidate Biomarkers for Early Detection of Glioblastoma in a Murine Model.
Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study.Journal of gastroenterology · 2026Article
- Reelin level in serum-derived extracellular vesicles predicts regression of M2BPGi-defined liver fibrosis following hepatitis C virus eradication by direct-acting antiviral agents.Journal of gastroenterology · 2026Article
- TurboID-Mediated Profiling of Glioblastoma-Derived Extracellular Vesicle Cargo Proteins.Journal of extracellular vesicles · 2025Article
- Deep and Quantitative Proteomic Profiling of Low Volume Mouse Serum Across the Lifespan.Research square · 2025Article
- Review
- Plasma-to-tumour tissue integrated proteomics using nano-omics for biomarker discovery in glioblastoma.Nature communications · 2025Article
- Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?International journal of molecular sciences · 2024Review
- Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management.Scientific reports · 2024Article
- Extracellular vesicles in the glioblastoma microenvironment: A diagnostic and therapeutic perspective.Molecular aspects of medicine · 2023Review
- Advances in Ultra-High-Resolution Mass Spectrometry for Pharmaceutical Analysis.Molecules (Basel, Switzerland) · 2023Review
- Strategies, considerations, and recent advancements in the development of liquid biopsy for glioblastoma: a step towards individualized medicine in glioblastoma.Neurosurgical focus · 2022Review
- Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients.Biomedicines · 2022Article
- Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 1 country.
Funding
Abstract
Glioblastoma Multiforme (GBM) is a brain tumor with a poor prognosis and low survival rates. GBM is diagnosed at an advanced stage, so little information is available on the early stage of the disease and few improvements have been made for earlier diagnosis. Longitudinal murine models are a promising platform for biomarker discovery as they allow access to the early stages of the disease. Nevertheless, their use in proteomics has been limited owing to the low sample amount that can be collected at each longitudinal time point. Here we used optimized microproteomics workflows to investigate longitudinal changes in the protein profile of serum, serum small extracellular vesicles (sEVs), and cerebrospinal fluid (CSF) in a GBM murine model. Baseline, pre-symptomatic, and symptomatic tumor stages were determined using non-invasive motor tests. Forty-four proteins displayed significant differences in signal intensities during GBM progression. Dysregulated proteins are involved in cell motility, cell growth, and angiogenesis. Most of the dysregulated proteins already exhibited a difference from baseline at the pre-symptomatic stage of the disease, suggesting that early effects of GBM might be detectable before symptom onset.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.